About Our Phase 1 Trial

XTMAB-16

WHAT IS
XTMAB-16?

An Investigational New Drug (IND) candidate developed by Xentria to suppress the physiologic response to tumor necrosis factor.

WHAT MEDICAL
CONDITION DOES
IT TARGET?

Sarcoidosis - A rare inflammatory disease that interferes with an organ’s structure and function.

WHAT HAPPENS?

Sarcoidosis is characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body.

Lungs are involved in approximately 90% of cases
Almost any organ can be affected by this rare disease
When left untreated, inflammation can lead to fibrosis which is permanent scarring of the organ tissue

KEY POINTS

Typically, spontaneous disease resolution can occur within 12-36 months of symptom onset
Severe cases of progressive disease can become advanced and chronic in approximately 25% of cases
Organ inflammation or fibrosis can cause many physical and psychological symptoms

What We Know

Sarcoidosis is a rare inflammatory disease that interferes with an organ’s structure and function.
Sarcoidosis is characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body.
The exact cause of sarcoidosis is unknown, researchers continue to explore genetic, seasonal and occupational influences.

Symptoms

~0% of cases the lungs are involved.

~0% of patients have eye symptoms.

~25% of patients develop a skin symptom.

5% of patients have heart-related symptoms.

Treatment

Many people experience mild symptoms and do not require treatment at any time. Treatment for this disease is often started to resolve symptoms or prevent disease progression.
Current guidelines also recommend treatments that may help improve health-related quality of life. If you do require treatment, it is important to work with your medical doctor to explore the treatment decision that works best for you.

COMPLICATIONS & SYMPTOMS

Quality of life

Fatigue
Mental health
Physical limitations
Disease burden

Pulmonary

Chronic cough
Shortness of breath
Wheezing
Loss of energy

Extrapulmonary

Sleep disturbance
Blurred or sensitive vision
Nose, cheek, lip, or ear discoloration
Muscle swelling and soreness

For More Information On Sarcoidosis

Xentria is partnered with the Foundation for Sarcoidosis Research (FSR). Additional information for patients and caregivers looking to connect with others facing this disease can be found here.

Visit FSR's Website